Twist Bioscience CEO sells 5,203 shares of stock

Two employee stock-option positions are listed, with different exercise prices and expiration dates.

Rhea-AI Filing Summary

Twist Bioscience Corp Chief Executive Officer Emily M. Leproust sold 5,203 shares of common stock in ten transactions on September 24, 2026, under a Rule 10b5-1 trading plan adopted June 15, 2026. The reported weighted-average sale prices and share amounts were 2,485 at $175.2313; 945 at $176.3917; 164 at $177.1699; 330 at $178.6683; 143 at $179.9331; 515 at $180.3911; 21 at $181.4519; 16 at $182.5000; 501 at $183.7641; and 83 at $184.6030 per share.

Insider Trade Summary 10b5-1

Net Seller: 5,203 shares

Net Sell 12 txns

Insider Leproust Emily M.

Role Chief Executive Officer

Sold 5,203 shs ($923K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	2,485	$175.2313	$435K
Sale	Common Stock F1, F3	945	$176.3917	$167K
Sale	Common Stock F1, F4	164	$177.1699	$29K
Sale	Common Stock F1, F5	330	$178.6683	$59K
Sale	Common Stock F1, F6	143	$179.9331	$26K
Sale	Common Stock F1, F7	515	$180.3911	$93K
Sale	Common Stock F1, F8	21	$181.4519	$4K
Sale	Common Stock F1, F9	16	$182.50	$3K
Sale	Common Stock F1, F10	501	$183.7641	$92K
Sale	Common Stock F1, F11	83	$184.603	$15K
holding	Employee Stock Option (right to buy) F12	--	--	--
holding	Employee Stock Option (right to buy) F13	--	--	--

Holdings After Transaction: Common Stock — 613,699 shares (Direct); Employee Stock Option (right to buy) — 196,240 contracts (Direct)

Footnotes (13)

1. F1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
2. F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $175 to $175.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $176 to $176.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
4. F4. Represents the weighted average sales price per share. The shares sold at prices ranging from $177.05 to $177.4 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
5. F5. Represents the weighted average sales price per share. The shares sold at prices ranging from $178.1 to $179 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
6. F6. Represents the weighted average sales price per share. The shares sold at prices ranging from $179.23 to $180.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
7. F7. Represents the weighted average sales price per share. The shares sold at prices ranging from $180.23 to $181.13 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
8. F8. Represents the weighted average sales price per share. The shares sold at prices ranging from $181.23 to $181.61 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
9. F9. Represents the weighted average sales price per share. The shares sold at prices ranging from $182.25 to $183.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
10. F10. Represents the weighted average sales price per share. The shares sold at prices ranging from $183.28 to $184.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
11. F11. Represents the weighted average sales price per share. The shares sold at prices ranging from $184.33 to $184.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
12. F12. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
13. F13. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.

Key Figures

Common shares sold: 5,203 shares Shares sold and weighted-average sale price: 2,485 shares at $175.2313 per share Shares sold and weighted-average sale price: 945 shares at $176.3917 per share +4 more

7 metrics

Common shares sold 5,203 shares Ten transactions on September 24, 2026

Shares sold and weighted-average sale price 2,485 shares at $175.2313 per share September 24, 2026

Shares sold and weighted-average sale price 945 shares at $176.3917 per share September 24, 2026

Shares sold and weighted-average sale price 164 shares at $177.1699 per share September 24, 2026

Shares sold and weighted-average sale price 330 shares at $178.6683 per share September 24, 2026

Underlying common shares subject to employee stock option 131,290 shares; $23.33 exercise price per share Direct option expiring October 23, 2029

Underlying common shares subject to employee stock option 64,950 shares; $67.85 exercise price per share Direct option expiring August 31, 2030

Key Terms

Rule 10b5-1 trading plan, weighted average sales price per share, performance stock options, vested and became exercisable

4 terms

Rule 10b5-1 trading plan financial

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price per share financial

"Represents the weighted average sales price per share"

performance stock options financial

"Represents performance stock options granted to the reporting person"

vested and became exercisable financial

"that vested and became exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did TWST CEO Emily M. Leproust sell?

Emily M. Leproust sold 5,203 shares of Twist Bioscience common stock in ten reported transactions on September 24, 2026.

What were the prices for Emily M. Leproust's TWST stock sales?

The ten reported weighted-average sale prices were $175.2313, $176.3917, $177.1699, $178.6683, $179.9331, $180.3911, $181.4519, $182.5000, $183.7641 and $184.6030 per share.

What TWST stock options are listed for Emily M. Leproust?

The reported option positions cover 131,290 common shares at an exercise price of $23.33, expiring October 23, 2029, and 64,950 common shares at an exercise price of $67.85, expiring August 31, 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/25/2026 - 04:17 PM Accepted by SEC EDGAR 09/25/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leproust Emily M.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2026		S(1)		2,485	D	$175.2313(2)	616,417	D
Common Stock	09/24/2026		S(1)		945	D	$176.3917(3)	615,472	D
Common Stock	09/24/2026		S(1)		164	D	$177.1699(4)	615,308	D
Common Stock	09/24/2026		S(1)		330	D	$178.6683(5)	614,978	D
Common Stock	09/24/2026		S(1)		143	D	$179.9331(6)	614,835	D
Common Stock	09/24/2026		S(1)		515	D	$180.3911(7)	614,320	D
Common Stock	09/24/2026		S(1)		21	D	$181.4519(8)	614,299	D
Common Stock	09/24/2026		S(1)		16	D	$182.5(9)	614,283	D
Common Stock	09/24/2026		S(1)		501	D	$183.7641(10)	613,782	D
Common Stock	09/24/2026		S(1)		83	D	$184.603(11)	613,699	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$23.33							(12)	10/23/2029	Common Stock	131,290		131,290	D
Employee Stock Option (right to buy)	$67.85							12/19/2022	08/31/2030	Common Stock	64,950		64,950(13)	D

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $175 to $175.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $176 to $176.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. Represents the weighted average sales price per share. The shares sold at prices ranging from $177.05 to $177.4 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

5. Represents the weighted average sales price per share. The shares sold at prices ranging from $178.1 to $179 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

6. Represents the weighted average sales price per share. The shares sold at prices ranging from $179.23 to $180.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

7. Represents the weighted average sales price per share. The shares sold at prices ranging from $180.23 to $181.13 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

8. Represents the weighted average sales price per share. The shares sold at prices ranging from $181.23 to $181.61 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

9. Represents the weighted average sales price per share. The shares sold at prices ranging from $182.25 to $183.03 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

10. Represents the weighted average sales price per share. The shares sold at prices ranging from $183.28 to $184.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

11. Represents the weighted average sales price per share. The shares sold at prices ranging from $184.33 to $184.96 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

12. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

13. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust	09/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)